Literature DB >> 30963603

A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.

Na Li1, Liwen Wei1,2, Xiaoyu Liu1, Hongjun Bai3, Yvonne Ye3, Dan Li3,4, Nan Li3, Ulrich Baxa5, Qun Wang4, Ling Lv6, Yun Chen7, Mingqian Feng2, Byungkook Lee3, Wei Gao1, Mitchell Ho3.   

Abstract

Wnt signaling is one of the key regulators of hepatocellular carcinoma (HCC) tumor progression. In addition to the classical receptor frizzled (FZD), various coreceptors including heparan sulfate proteoglycans (HSPGs) are involved in Wnt activation. Glypican-3 (GPC3) is an HSPG that is overexpressed in HCC and functions as a Wnt coreceptor that modulates HCC cell proliferation. These features make GPC3 an attractive target for liver cancer therapy. However, the precise interaction of GPC3 and Wnt and how GPC3, Wnt, and FZD cooperate with each other are poorly understood. In this study, we established a structural model of GPC3 containing a putative FZD-like cysteine-rich domain at its N-terminal lobe. We found that F41 and its surrounding residues in GPC3 formed a Wnt-binding groove that interacted with the middle region located between the lipid thumb domain and the index finger domain of Wnt3a. Mutating residues in this groove significantly inhibited Wnt3a binding, β-catenin activation, and the transcriptional activation of Wnt-dependent genes. In contrast with the heparan sulfate chains, the Wnt-binding groove that we identified in the protein core of GPC3 seemed to promote Wnt signaling in conditions when FZD was not abundant. Specifically, blocking this domain using an antibody inhibited Wnt activation. In HCC cells, mutating residue F41 on GPC3 inhibited activation of β-catenin in vitro and reduced xenograft tumor growth in nude mice compared with cells expressing wild-type GPC3.
Conclusion: Our investigation demonstrates a detailed interaction of GPC3 and Wnt3a, reveals the precise mechanism of GPC3 acting as a Wnt coreceptor, and provides a potential target site on GPC3 for Wnt blocking and HCC therapy.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30963603      PMCID: PMC6783318          DOI: 10.1002/hep.30646

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

Review 1.  Alternative Wnt pathways and receptors.

Authors:  Renée van Amerongen
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

2.  Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas.

Authors:  Satoshi Nagayama; Chikako Fukukawa; Toyomasa Katagiri; Takeshi Okamoto; Tomoki Aoyama; Naoki Oyaizu; Masayuki Imamura; Junya Toguchida; Yusuke Nakamura
Journal:  Oncogene       Date:  2005-09-15       Impact factor: 9.867

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

4.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

5.  Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Authors:  Zeyan Pan; Shengmeng Di; Bizhi Shi; Hua Jiang; Zhimin Shi; Ying Liu; Yi Wang; Hong Luo; Min Yu; Xiuqi Wu; Zonghai Li
Journal:  Cancer Immunol Immunother       Date:  2018-08-04       Impact factor: 6.968

6.  First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Philip J Gold; Anthony B El-Khoueiry; Thomas A Abrams; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A Philip
Journal:  Clin Cancer Res       Date:  2013-01-29       Impact factor: 12.531

7.  Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

Authors:  Wenpeng Li; Linjie Guo; Purva Rathi; Ekaterina Marinova; Xiuhua Gao; Meng-Feng Wu; Hao Liu; Gianpietro Dotti; Stephen Gottschalk; Leonid S Metelitsa; Andras Heczey
Journal:  Hum Gene Ther       Date:  2016-08-16       Impact factor: 5.695

8.  Structural basis of Wnt recognition by Frizzled.

Authors:  Claudia Y Janda; Deepa Waghray; Aron M Levin; Christoph Thomas; K Christopher Garcia
Journal:  Science       Date:  2012-05-31       Impact factor: 47.728

9.  Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.

Authors:  A Bengochea; M M de Souza; L Lefrançois; E Le Roux; O Galy; I Chemin; M Kim; J R Wands; C Trepo; P Hainaut; J-Y Scoazec; L Vitvitski; P Merle
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

Review 10.  Glypicans.

Authors:  Jorge Filmus; Mariana Capurro; Jonathan Rast
Journal:  Genome Biol       Date:  2008-05-22       Impact factor: 13.583

View more
  38 in total

1.  Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display.

Authors:  Ruonan Feng; Ruixue Wang; Jessica Hong; Christopher M Dower; Brad St Croix; Mitchell Ho
Journal:  Antib Ther       Date:  2020-02-17

Review 2.  Liver regeneration: biological and pathological mechanisms and implications.

Authors:  George K Michalopoulos; Bharat Bhushan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-08-06       Impact factor: 46.802

Review 3.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 4.  Excavating proteoglycan structure-function relationships: modern approaches to capture the interactions of ancient biomolecules.

Authors:  Meg Critcher; Mia L Huang
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

5.  Inactivation of Ihh in Sp7-Expressing Cells Inhibits Osteoblast Proliferation, Differentiation, and Bone Formation, Resulting in a Dwarfism Phenotype with Severe Skeletal Dysplasia in Mice.

Authors:  YunFei Wang; Zhengquan Dong; Ruijia Yang; Sujing Zong; Xiaochun Wei; Chunfang Wang; Li Guo; Jian Sun; Haoqian Li; Pengcui Li
Journal:  Calcif Tissue Int       Date:  2022-06-22       Impact factor: 4.000

6.  Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.

Authors:  Dan Li; Nan Li; Yi-Fan Zhang; Haiying Fu; Mingqian Feng; Dina Schneider; Ling Su; Xiaolin Wu; Jing Zhou; Sean Mackay; Josh Kramer; Zhijian Duan; Hongjia Yang; Aarti Kolluri; Alissa M Hummer; Madeline B Torres; Hu Zhu; Matthew D Hall; Xiaoling Luo; Jinqiu Chen; Qun Wang; Daniel Abate-Daga; Boro Dropublic; Stephen M Hewitt; Rimas J Orentas; Tim F Greten; Mitchell Ho
Journal:  Gastroenterology       Date:  2020-02-12       Impact factor: 22.682

Review 7.  Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications.

Authors:  Hejiao English; Jessica Hong; Mitchell Ho
Journal:  Antib Ther       Date:  2020-01-21

8.  Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors.

Authors:  Lin Yu; Xi Yang; Nan Huang; Meng Wu; Heng Sun; Qilin He; Qiaoli Lang; Xiangang Zou; Zuohua Liu; Jianhua Wang; Liangpeng Ge
Journal:  Invest New Drugs       Date:  2020-11-19       Impact factor: 3.850

Review 9.  Syndecan receptors: pericellular regulators in development and inflammatory disease.

Authors:  Sandeep Gopal; Samantha Arokiasamy; Csilla Pataki; James R Whiteford; John R Couchman
Journal:  Open Biol       Date:  2021-02-10       Impact factor: 6.411

10.  Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.

Authors:  Bryan D Fleming; Daniel J Urban; Matthew D Hall; Thomas Longerich; Tim F Greten; Ira Pastan; Mitchell Ho
Journal:  Hepatology       Date:  2020-01-27       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.